

Travis T Wager

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2151795/publications.pdf>

Version: 2024-02-01

40
papers

4,329
citations

186265

28
h-index

289244

40
g-index

40
all docs

40
docs citations

40
times ranked

5444
citing authors

#	ARTICLE	IF	CITATIONS
1	Harnessing Preclinical Data as a Predictive Tool for Human Brain Tissue Targeting. <i>ACS Chemical Neuroscience</i> , 2021, 12, 1007-1017.	3.5	6
2	Design, Optimization, and Study of Small Molecules That Target Tau Pre-mRNA and Affect Splicing. <i>Journal of the American Chemical Society</i> , 2020, 142, 8706-8727.	13.7	39
3	A perspective on the physicochemical and biopharmaceutical properties of marketed antiseizure drugs—From phenobarbital to cenobamate and beyond. <i>Epilepsia</i> , 2020, 61, 1543-1552.	5.1	26
4	Systems approach reveals photosensitivity and PER2 level as determinants of clock-modulator efficacy. <i>Molecular Systems Biology</i> , 2019, 15, e8838.	7.2	29
5	In Vitro—In Vivo Extrapolation of Key Transporter Activity at the Blood—Brain Barrier. <i>Drug Metabolism and Disposition</i> , 2019, 47, 405-411.	3.3	32
6	Validation of Human MDR1-MDCK and BCRP-MDCK Cell Lines to Improve the Prediction of Brain Penetration. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2476-2483.	3.3	46
7	Late-Stage Microsomal Oxidation Reduces Drug—Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 68-72.	2.8	31
8	Identification and Profiling of a Selective and Brain Penetrant Radioligand for in Vivo Target Occupancy Measurement of Casein Kinase 1 (CK1) Inhibitors. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1995-2004.	3.5	21
9	Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects. <i>ACS Chemical Neuroscience</i> , 2017, 8, 165-177.	3.5	17
10	Quantitative Assessment of the Impact of Fluorine Substitution on P-Glycoprotein (P-gp) Mediated Efflux, Permeability, Lipophilicity, and Metabolic Stability. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5284-5296.	6.4	57
11	Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery. <i>ACS Chemical Neuroscience</i> , 2016, 7, 767-775.	3.5	338
12	Discovery and Preclinical Profiling of 3-[4-(Morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzotrile (PF-06447475), a Highly Potent, Selective, Brain Penetrant, and in Vivo Active LRRK2 Kinase Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 419-432.	6.4	147
13	Casein Kinase 1 Inhibitor PF-5006739 Attenuates Opioid Drug-Seeking Behavior. <i>ACS Chemical Neuroscience</i> , 2014, 5, 1253-1265.	3.5	29
14	Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 4132-4140.	2.2	26
15	A Novel Mechanism Controlling Resetting Speed of the Circadian Clock to Environmental Stimuli. <i>Current Biology</i> , 2014, 24, 766-773.	3.9	46
16	Ligand—Protein Interactions of Selective Casein Kinase 1 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6819-6828.	6.4	25
17	Improving the Odds of Success in Drug Discovery: Choosing the Best Compounds for in Vivo Toxicology Studies. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9771-9779.	6.4	41
18	Design and Selection Parameters to Accelerate the Discovery of Novel Central Nervous System Positron Emission Tomography (PET) Ligands and Their Application in the Development of a Novel Phosphodiesterase 2A PET Ligand. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4568-4579.	6.4	172

#	ARTICLE	IF	CITATIONS
19	Csnk1e Is a Genetic Regulator of Sensitivity to Psychostimulants and Opioids. <i>Neuropsychopharmacology</i> , 2012, 37, 1026-1035.	5.4	60
20	Getting the MAX out of Computational Models: The Prediction of Unbound-Brain and Unbound-Plasma Maximum Concentrations. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 515-519.	2.8	2
21	Strategies to minimize CNS toxicity: <i>in vitro</i> high-throughput assays and computational modeling. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 531-542.	3.3	33
22	Discovery of Two Clinical Histamine H ₃ Receptor Antagonists: <i>trans</i> -N-Ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and <i>trans</i> -3-Fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764). <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7602-7620.	6.4	80
23	Central Modulation of Circadian Rhythm via CK1 Inhibition for Psychiatric Indications. <i>Annual Reports in Medicinal Chemistry</i> , 2011, 46, 33-51.	0.9	3
24	Strategies to optimize the brain availability of central nervous system drug candidates. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 371-381.	5.0	48
25	Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties. <i>ACS Chemical Neuroscience</i> , 2010, 1, 435-449.	3.5	763
26	Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 15240-15245.	7.1	219
27	Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, <i>In Vitro</i> ADME, and Safety Attributes. <i>ACS Chemical Neuroscience</i> , 2010, 1, 420-434.	3.5	381
28	Selective Inhibition of Casein Kinase 1 Minimally Alters Circadian Clock Period. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 330, 430-439.	2.5	157
29	Physicochemical drug properties associated with <i>in vivo</i> toxicological outcomes: a review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 921-931.	3.3	131
30	Physicochemical drug properties associated with <i>in vivo</i> toxicological outcomes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4872-4875.	2.2	749
31	Glycogen Synthase Kinase-3 (GSK-3): A Kinase with Exceptional Therapeutic Potential. <i>Annual Reports in Medicinal Chemistry</i> , 2005, 40, 135-147.	0.9	3
32	A Direct and Mild Conversion of Tertiary Aryl Amides to Methyl Esters Using Trimethyloxonium Tetrafluoroborate: A Very Useful Complement to Directed Metalation Reactions. <i>Tetrahedron</i> , 2000, 56, 9875-9883.	1.9	48
33	Reductive cleavage of N—O bonds in hydroxylamines and hydroxamic acid derivatives using samarium diiodide. <i>Tetrahedron</i> , 1999, 55, 11755-11772.	1.9	104
34	An Especially Convenient Stereoselective Reduction of β -Hydroxy Ketones to Anti 1,3 Diols Using Samarium Diiodide. <i>Journal of Organic Chemistry</i> , 1999, 64, 2172-2173.	3.2	81
35	Total Syntheses of (âˆ’)-Lycoricidine, (+)-Lycoricidine, and (+)-Narciclasine via 6-exoCyclizations of Substituted Vinyl Radicals with Oxime Ethers. <i>Journal of the American Chemical Society</i> , 1999, 121, 5176-5190.	13.7	90
36	A Second-Generation Radical-Based Synthesis of (+)-7-Deoxypancratistatin. <i>Journal of Organic Chemistry</i> , 1998, 63, 9164-9165.	3.2	56

#	ARTICLE	IF	CITATIONS
37	Total Synthesis of ent-Lycoricidine via a Thiyl Radical Addition~Cyclization Sequence. <i>Journal of Organic Chemistry</i> , 1996, 61, 8366-8367.	3.2	65
38	Reductive cleavage of Ni—O bonds in hydroxylamine and hydroxamic acid derivatives using SmI ₂ /THF. <i>Tetrahedron Letters</i> , 1995, 36, 7419-7422.	1.4	120
39	The Scientist-in-Residence Program: A Chemistry-Based Outreach Initiative. <i>Journal of Chemical Education</i> , 1994, 71, 864.	2.3	4
40	Synthesis of (+)-(R)-6-Ethyl-2,3-dihydro-2-methyl-4 <i>H</i> pyran-4-one -Sex-Pheromone Component of the Male Swift Moth <i>Hepialus hecta</i> L. <i>Synthetic Communications</i> , 1993, 23, 87-95.	2.1	4